Genetic Technologies
Genetic Technologies Fiscal Year 2021 Revenues Soar on COVID-19 Test Alliance
Genetic Technologies recently signed an agreement to commercialize its test for assessing a COVID-19 patient's risk of severe disease in the US with Infinity Biologix.
Genetic Technologies to Acquire DTC Genetic Test Provider EasyDNA for $4M
EasyDNA sells a range of paternity, oncology, animal genomics, and health and wellness genetic tests through 12 agreements with labs across the world.
Genetic Technologies Inks US Commercialization Deal for COVID-19 Risk Test With Infinity Biologix
The test is designed to assess the risk of a person developing severe disease if they contract COVID-19 based on a combination of genetic and clinical factors.
Genetic Technologies to Raise $6.6M in Direct Offering
The company said it had signed definitive agreements to sell $6.6 million of its American Depository Shares to undisclosed institutional investors.
Genetic Technologies Lands Distribution Rights to Taliaz Antidepressant Drug Selection Tools
The products analyze various datasets including a patient's genetic and metabolic profiles, clinical history, and demographics to inform prescribing decisions.